Sequana Medical NV (STU:2SE) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2SE Sequana Medical NV STU:2SE
34 GF Score
Price €0.51
GF Value €0.19
! 12 Warning Signs
View Full Analysis

What is Sequana Medical NV FFO per Share?

FFO per Share only applies to REITs.

STU:2SE
34GF Score
Sequana Medical NV STU:2SE
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sequana Medical NV (STU:2SE) Overvalued in 2026?

Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued. The current stock price of €0.51 is trading 168.9% above its estimated GF Value™ of €0.19.

Key valuation signals for STU:2SE:

  • FFO per Share:
  • GF Value™: €0.19 vs. price of €0.51 (168.9% above fair value)
  • GF Score™: 34/100 with 12 warning signs

No single metric tells the full story. See the STU:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sequana Medical NV Business Description

Other Exchanges SEQUA:Belgium
Address Kortrijksesteenweg 1112, bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
34GF Score

Get the complete analysis for STU:2SE

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.19
GF Value